). Thirty-eight adverse events possibly related to daptomycin occurred in 28 patients (7%); increased blood creatine kinase level (7 patients [1.8%]) was the most common adverse event. Adverse-event rates were similar across all dosing regimens. Conclusion. In these patients undergoing hemodialysis, daptomycin was a well-tolerated treatment for gram-positive infections across several doses and dosing frequencies. Further study in prospective trials is warranted.
caused by S. aureus, are eliminated primarily through the kidneys, their administration can be challenging in this patient population. In addition, the potential for toxicity may increase as the plasma concentrations of the drug increase due to reduced renal clearance. Vancomycin, which has been the standard therapy for MRSA infection, shares these characteristics. 5 In addition, vancomycin efficacy appears to be lower against MRSA infections, with elevated vancomycin minimum inhibitory concentration (MIC) values in the susceptible range. [6] [7] [8] Although extremely rare, the first United States reports of vancomycin-resistant S. aureus were in patients receiving hemodialysis. 9, 10 In addition, renal failure is a common independent risk factor for mortality in various infection types and clinical settings. [11] [12] [13] The factors contributing to increased mortality may be antibiotic related or due to patient characteristics that complicate their response to therapy. In either case, additional information on antibiotic use in this population is needed.
Daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA) is a cyclic lipopeptide that causes rapid, concentration-dependent bacterial cell death against gram-positive organisms. 14 The activity of daptomycin, vancomycin, and linezolid against S. aureus isolates from bacteremic patients receiving hemodialysis is similar, with 99.8-100% susceptibility. 15 Daptomycin has demon-strated similar efficacy to vancomycin and semi-synthetic penicillins in randomized, multicenter trials of complicated skin and skin structure infections and bacteremia and endocarditis, although patients were limited to those with normal to moderately reduced renal function. 16, 17 Pharmacokinetic analysis reveals that daptomycin is more than 90% bound to plasma proteins and primarily is excreted unchanged by the kidneys in healthy volunteers.
In studies of patients receiving hemodialysis, protein binding is similar at 90%, clearance is approximately one third, and the corresponding half-life and area under the concentration-time curve are more than doubled compared with those parameters in patients who have normalto-moderate renal impairment. [18] [19] [20] In patients treated with hemodialysis, the recommended dosing regimen of daptomycin is 4 mg/kg every 48 hours for complicated skin and skin structure infections and 6 mg/kg every 48 hours for S. aureus bacteremia or right-sided endocarditis. 20 When possible, daptomycin should be administered after hemodialysis on hemodialysis days. 20 This may be difficult when the currently approved every-48-hour dosing regimen falls on days opposite the thrice-weekly hemodialysis schedule commonly used by patients. Consequently, the daptomycin dosing regimen that is used in the real-life management of these patients may fall outside of recommended labeling, since most patients receive intravenous antibiotics during or immediately after their dialysis session.
The objective of this study was to describe the safety profile of daptomycin administered using a variety of doses and dosing schedules in the overall treatment of patients receiving hemodialysis who had probable or confirmed gram-positive infections, by analyzing data from a large, retrospective, multicenter registry.
Methods

Data Source
The Cubicin Outcomes Registry and Experience (CORE) is a multicenter, retrospective, noncomparative, observational registry implemented to collect standard-of-care data on daptomycin use in different types of gram-positive infections and patients, including those receiving hemodialysis. 21 From the time period of 2005-2008, patient data and clinical outcomes were collected in the United States for the CORE registry. All sites were required to obtain appropriate local or central institutional review board approval, and sites were chosen if they could provide data on a prespecified number of patients and represented a variety of treatment settings, including hospitals and outpatient centers. Patient records were included in the registry if the patients were treated with one or more doses of daptomycin and were not administered daptomycin as part of a clinical trial. 21 Data were abstracted from patient records and verified by the investigators at each site. For the purpose of this analysis, the safety of patients receiving intermittent hemodialysis was assessed overall and based on their final dosing frequency of daptomycin administration when available: every 48 hours, 3 times/week, or every 24 hours.
Safety Assessment
All patients who received any dose or dosing frequency of daptomycin were included in the safety analysis. Throughout the daptomycin treatment period and up to 30 days after the last dose of daptomycin, changes in physical findings, clinical signs and symptoms, and laboratory values consistent with serious and nonserious adverse events were to be documented. Adverse events were considered serious if they resulted in any of the following: death, a life-threatening state, disability or incapacity, hospitalization, congenital anomaly or birth defect, or an important medical event.
The following additional information was collected for all adverse events: day of onset relative to daptomycin initiation, severity (mild, moderate, severe), relationship to daptomycin (not related, possibly related), action taken with daptomycin (none, stopped permanently, dose reduced, stopped temporarily), other action taken (none, concomitant drug, procedure performed, other), outcome (resolved, resolved with residual effects, death, ongoing, unknown), and resolution (day of resolution or day of last contact relative to daptomycin start). All adverse events were determined by the investigators by using International Committee on Harmonisation E2A definitions of seriousness and severity. 22 
Statistical Analysis
Continuous variables were reported as mean ± SD or median and range. Categoric variables In the hemodialysis population overall, more than half of the patients were female, older than 51 years, and in the hospital 2 days before daptomycin administration (Table 1) . Almost all patients received daptomycin as an inpatient, and 33% of all patients received some part of their daptomycin treatment in an intensive care unit setting. Hypertension and diabetes mellitus were the most common underlying diseases. No significant differences were seen in the demographics among groups by daptomycin dosing frequency except that the every-48-hours group had the highest rate of daptomycin treatment in an intensive care unit and the every-24-hours group had the highest predominance of cancer.
Infection Types and Pathogens
Most patients were treated for bacteremia; skin and skin structure infection was the next most common type of infection. No significant differences were noted among daptomycin dosing frequency groups when categorized by primary infection types except for catheterrelated bacteremia and skin and skin structure infections ( 
Dose and Frequency of Daptomycin
The median final daptomycin dose was 6 mg/kg (range 2-14.75 mg/kg); patients with skin and skin structure infection and/or urinary tract infections or pyelonephritis received a median of 4 mg/kg (range 2-10 mg/kg), and those with all other infection types received a median of 6 mg/kg (range 2-14.75 mg/kg). The median dose in patients receiving treatment every 24 hours was 4 mg//kg (range 2-7 mg/kg) compared with 6 mg/kg (range 3-14.75 mg/kg) in the every-48-hours group, and 6 mg/kg (range 3-9.5 mg/kg) in the 3 times/week group. By infection type, the every-24-hours group had the lowest median dose for all categories except for skin and skin structure infections and the group of other infections. Data were not collected to determine if the daptomycin dose was based on ideal or total body weight.
The median duration of therapy was 12 days (range 1-84 days). The median daptomycin duration of therapy was longest for bone and joint infections (17.5 days) and endocarditis (15 days) and was shortest for skin and skin structure infections and urinary tract infections or pyelonephritis (10 days) and the group of other infections (6 days). The median duration was shortest in the every-24-hours group (10.5 days) compared with the every-48-hours group (12 days) and 3 times/week group (15 days, p=0.01). For patients who received previous and/or follow-up antibiotics, the daptomycin duration represents a portion of the total duration of therapy.
Safety
A total of 200 adverse events occurred in 94 patients (24%) overall, with 38 adverse events in 28 patients (7%) classified as possibly related to daptomycin. The occurrence of adverse events including those possibly related to daptomycin was not affected significantly by dosing frequency (Table 3) . Of those possibly related to daptomycin, increased blood creatine kinase level was the most common, occurring in 7 patients (1.8%); the frequency of increased creatine kinase level was not significantly different among the dosing frequency groups. Rash and eosinophilia were reported in 4 (1%) and 3 (0.8%) patients, respectively. Diarrhea, hyponatremia, pyrexia, and thrombocytopenia occurred in 2 patients (0.5%) each. Nine adverse events (bacterial sepsis, eosinophilia, urticaria, renal insufficiency, pancytopenia, catheter site discharge, Klebsiella infection, Pseudomonas infection, and rhabdomyolysis) in 6 patients (2%) were reported as serious and possibly related to daptomycin. Twenty patients (5%) discontinued daptomycin because of an adverse event; 12 (3%) had an adverse event that was possibly related to daptomycin. In addition, no significant difference in number of patients experiencing any adverse event was observed when stratified by daptomycin dose (44/166 [27%] for < 6 mg/kg vs 48/217 [22%] for ≥ 6 mg/kg, p=0.3). The overall mortality rate was 11% (42/393): 12% (31/251) for the every-48-hour group, 6% (5/87) for the 3 times/week group, 9% (3/32) for the every-24-hour group, and 13% (3/23) in the remaining patients.
Discussion
In patients treated with hemodialysis, the administration of many drugs is challenging, especially those drugs that are eliminated through the kidneys. For antibiotics, this is especially problematic since appropriate dosing is necessary in order to eradicate the pathogen(s), prevent development of resistance, and avoid toxicity.
Since its introduction, daptomycin has been used frequently across a variety of infection types with good clinical outcomes. 23 The data from this analysis of the CORE registry from [2005] [2006] [2007] [2008] showed that the rate of adverse events from daptomycin was similar across dosing frequency groups.
There has been a need for additional safety data with daptomycin in this population as slower elimination and higher troughs might lead to higher adverse-event rates. However, rates of adverse events generally were similar to those found in randomized, multicenter trials of daptomycin. 16, 17 With respect to adverse events judged to be possibly related to daptomycin, only 2% were classified as serious. An elevated creatine kinase level was observed in less than 2% of patients in the population evaluated in the safety analysis. It is noteworthy that daptomycin yielded similar results across all dosing frequency groups without the need for therapeutic drug monitoring, which is often recommended for vancomycin and teicoplanin. The every-24-hour dosing interval is not recommended in patients receiving hemodialysis since the prolonged halflife will lead to higher trough concentrations than those seen in patients with normal renal function. Data accumulated to date suggest that daptomycin-associated muscle toxicity is related to an inadequate amount of time between doses where the minimum serum concentration may be elevated. 24 The daptomycin dose was not significantly different between those who developed an elevated creatine kinase level and those who did not. It is unknown if the lower dose used in patients receiving daptomycin every 24 hours may have mitigated the occurrence of adverse events. Further data are expected from an ongoing prospective study of patients with moderate or severe renal dysfunction comparing daptomycin with vancomycin for patients with skin and skin structure infections or S. aureus bacteremia. 25 The overall mortality rate of 11% in this analysis is similar to published data in this population. One group of authors investigated the outcomes of first-time infections in hospitalized patients receiving hemodialysis. 26 An outcome of death occurred in 13.8% of firsttime infections. The types of infections were similar in frequency to those described in this analysis, with a preponderance of bacteremia and access-related infections and lower rates of cardiac, skin, and urinary tract infections. One notable difference was the absence of pulmonary infections in the CORE registry due to daptomycin's lack of efficacy in this setting. 20 
Limitations
The retrospective nature of the registry has several important limitations that prevent drawing firm conclusions regarding the safety of daptomycin in the treatment of gram-positive infections in the hemodialysis population. There was no control group; all patients in the registry had received daptomycin in addition to other treatment options including concomitant antibiotics and surgical interventions as appropriate. Many variables were not controlled, as patients were managed at the discretion of their physicians, which, while a limitation, also provides real-world perspective. Thus, safety outcomes and mortality may have been influenced by factors other than the use of daptomycin.
The patient population was diverse, with a variety of infections and pathogens. Although reflective of real-world clinical practice, the number of subjects in any particular subgroup was small. Susceptibility data were incomplete, making it difficult to identify any association between in vitro activity of daptomycin and mortality. There was no patient follow-up after the completion of daptomycin therapy; thus, identifying late adverse events was not possible. Finally, details on the administration of hemodialysis, information on different variables such as duration, type of filter, and flow rates were not collected as part of the CORE registry during this time period. These and other factors may alter significantly the amount of drug clearance during a dialysis session. 27 This information was captured in 2009, and 66% of patients undergoing intermittent dialysis received their daptomycin after dialysis. Although the product labeling of daptomycin recommends administration after hemodialysis sessions, 20 strict assurance that study patients received it in such a manner was not captured.
Conclusion
The safety data in this analysis of daptomycin in patients receiving hemodialysis who had a variety of gram-positive infections suggest that daptomycin as part of the standard of care in this setting may be a well-tolerated treatment option. The adverse events reported during daptomycin treatment appeared similar across all doses and dosing frequencies that are commonly used to treat infections in patients receiving hemodialysis, including 3 times/week. Further study in prospective clinical trials is warranted.
